Paper Details

  1. Home
  2. Paper Details

Efficacy of novel &#946;<sub>3</sub> -adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study.

Author: GotohMomokazu, HashimotoKeita, KakizakiHidehiro, MasumoriNaoya, MinemuraKazuyoshi, NagaiShinji, TakahashiSatoru, TakedaMasayuki, YokoyamaOsamu, YoshidaMasaki

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Vibegron significantly reduced the frequency of nocturnal voiding in patients with overactive bladder compared to placebo. The study also found that vibegron treatment was associated with a greater mean volume of nocturnal voids and a greater volume of the first nocturnal voiding compared to placebo.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: To investigate the efficacy of vibegron on nocturia in patients with overactive bladder. METHODS: Among the Japanese overactive bladder patients enrolled in the placebo-controlled, multicenter, randomized, double-blind phase 3 study of vibegron, a total of 669 patients with nocturia (≥1...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912249/

データ提供：米国国立医学図書館（NLM）

Vibegron: A New Oasis for Nocturia in Overactive Bladder

Nocturia, the need to urinate frequently at night, can significantly disrupt sleep and quality of life. This research investigates the efficacy of vibegron, a novel β3-adrenoreceptor agonist, in treating nocturia in patients with overactive bladder. The study, akin to a search for a cool oasis in a scorching desert, aims to alleviate the discomfort and improve sleep quality in individuals struggling with nocturia.

Promising Results: Reduced Nocturia and Improved Sleep

The study revealed that vibegron significantly reduced the frequency of nocturnal voiding and improved hours of undisturbed sleep in patients with overactive bladder. This is like discovering a refreshing oasis in the desert of nocturia, providing a haven of relief and a path to a more restful night's sleep. This study demonstrates the potential of vibegron as a promising new treatment option for nocturia.

A New Hope for Overactive Bladder Patients

The findings of this study offer a glimmer of hope for patients struggling with overactive bladder and nocturia, providing a potential treatment option that can improve sleep quality and enhance overall well-being. It is like finding a new route through the desert of overactive bladder, leading to a more comfortable and fulfilling life. This research underscores the importance of continued research and innovation in the field of urology, seeking to improve the lives of individuals affected by this common condition.

Dr. Camel's Conclusion

This research reminds us that even seemingly minor inconveniences, like nocturia, can have a significant impact on quality of life. The development of effective treatments for overactive bladder is a testament to the tireless efforts of medical researchers. We must continue to explore new frontiers in medicine, seeking to alleviate suffering and improve the well-being of all those who need it most.

Date :
  1. Date Completed 2020-06-15
  2. Date Revised 2020-06-15
Further Info :

Pubmed ID

30557916

DOI: Digital Object Identifier

PMC6912249

Related Literature

Article Analysis
・Effects of vibegron
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.